PHARMACODYNAMIC EFFECTS OF ATACICEPT IN SLE PATIENTS: 52-WEEK DATA FROM THE APRIL-SLE TRIAL

被引：0
|
作者：
Wofsy, D. [1 ]
Gordon, C. [2 ]
Licu, D. [3 ]
Copt, S. [3 ]
Rossi, C. Pena [3 ]
Isenberg, D. [4 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Birmingham, Birmingham, W Midlands, England
[3] Merck Serono SA, Geneva, Switzerland
[4] UCL, London, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
    Isenberg, David
    Gordon, Caroline
    Licu, Daiana
    Copt, Samuel
    Rossi, Claudia Pena
    Wofsy, David
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (11) : 2006 - 2015
  • [2] Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
    Isenberg, David A.
    Wofsy, David
    Li, Yong
    Licu, Daiana
    Wax, Stephen D.
    Gordon, Caroline
    Rossi, Claudia Pena
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S1089 - S1089
  • [3] EFFICACY AND SAFETY OF ATACICEPT FOR PREVENTION OF FLARES IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 52-WK DATA (APRIL-SLE TRIAL)
    Isenberg, D.
    Gordon, C.
    Licu, D.
    Copt, S.
    Rossi, C. Pena
    Wofsy, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 258 - 259
  • [4] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
    Isenberg, David
    Li, Yong
    Wax, Stephen
    Wofsy, David
    Gordon, Caroline
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16
  • [5] Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
    David Isenberg
    Yong Li
    Stephen Wax
    David Wofsy
    Caroline Gordon
    [J]. Arthritis Research & Therapy, 16
  • [6] EFFECTS OF ATACICEPT ON DISEASE ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: APRIL-SLE RANDOMIZED TRIAL
    Gordon, C.
    Isenberg, D.
    Li, Y.
    Wax, S.
    Wofsy, D.
    Rossi, C. Pena
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 77 - 77
  • [7] IDENTIFYING LUPUS PATIENT SUBSETS AND SPECIFIC PHARMACODYNAMIC CHANGES THROUGH IMMUNE CELL DECONVOLUTION OF GENE EXPRESSION DATA IN ATACICEPT-TREATED PATIENTS IN THE APRIL-SLE STUDY
    Samy, Eileen
    Studham, Matthew
    Kao, Amy
    Haselmayer, Philipp
    Chang, Peter
    Rolfe, P. Alexander
    Wofsy, David
    Demartino, Julie
    Townsend, Robert
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 783 - 783
  • [8] Trial of atacicept in patients with systemic lupus erythematosus (SLE).
    Dall'Era, Maria
    Chakravarty, Eliza
    Genovese, Mark
    Wallace, Daniel
    Kavanaugh, Arthur
    Kalunian, Kenneth
    Dhar, Patricia
    Pena-Rossi, Claudia
    Wofsy, David
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (12): : 4042 - 4043
  • [9] Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
    Gordon, Caroline
    Wofsy, David
    Wax, Stephen
    Li, Yong
    Rossi, Claudia Pena
    Isenberg, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (01) : 122 - 130
  • [10] Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
    Borg, Alexander
    Gomez, Alvaro
    Cederlund, Arvid
    Cobar, Flordelyn
    Qiu, Victor
    Lindblom, Julius
    Emamikia, Sharzad
    Enman, Yvonne
    Pettersson, Susanne
    Parodis, Ioannis
    [J]. RHEUMATOLOGY, 2021, 60 (09) : 4205 - 4217
12345